Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase up to an additional 1,000,050 common shares. The common shares are listed on the NASDAQ Global Select Market under the symbol “IFRX.”

Based in Jena, Germany, InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx’s lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity, safety and tolerability in multiple clinical settings. InflaRx is developing IFX-1 for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease, as well as for the treatment of a wide array of complement-mediated diseases with significant unmet needs. 

The Davis Polk corporate team included partners Sophia Hudson and Deanna L. Kirkpatrick and associates Milson C. Yu and Roohi Gupte. The tax team included partner Michael Mollerus and associate Erin Harvey. The intellectual property and technology team included counsel David R. Bauer and associate Jesse L. Hallock. The executive compensation team included partner Veronica M. Wissel and associate Akansha Mishra. All members of the Davis Polk team are based in the New York office.

Copy link to share post